Organization
Gilead
29 clinical trials
5 abstracts
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)Status: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-11-26
Clinical trial
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)Status: Terminated, Estimated PCD: 2021-03-16
Clinical trial
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)Status: Active (not recruiting), Estimated PCD: 2021-03-18
Clinical trial
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Status: Completed, Estimated PCD: 2023-01-12
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-12-02
Clinical trial
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelStatus:
Clinical trial
A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient SettingStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-22
Clinical trial
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelStatus:
Clinical trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified CellsStatus: , Estimated PCD: 2040-12-01
Clinical trial
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2020-09-10
Clinical trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell LymphomaStatus: Terminated, Estimated PCD: 2021-05-07
Clinical trial
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced CancersStatus: Terminated, Estimated PCD: 2021-06-30
Clinical trial
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)Status: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2018-12-17
Clinical trial
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.Status:
Clinical trial
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaStatus: Terminated, Estimated PCD: 2021-02-12
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Clinical trial
A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus: Terminated, Estimated PCD: 2024-05-18
Clinical trial
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2030-10-01
Abstract
Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).Org: Dana-Farber Cancer Institute, Gilead, Stanford University School of Medicine, City of Hope National Medical Center, The University of Kansas Medical Center,
Abstract
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: Moffitt Cancer Center, University of Washington & Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, CHU Rennes, Université Rennes,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,